Sania Therapeuticsis building precision gene therapies, combining targeted delivery of a therapeutic with a titratable activator to redefine nervous system therapies and maximize safety and efficacy.
Sania’s proprietary platform takes a “human-first” approach, recreating human neural circuits in the lab to develop cell-type specific gene delivery vectors. Sania’s system for neuromodulation normalizes electrical activity in these neural circuits, allowing them to treat a broad range of prevalent disorders.
SECTOR
Health Sciences
INVESTED
2023
STATUS
Active
HQ
London, UK
FOUNDERS
Andy Murray, PhD
Robert Brownstone, MD/PhD
Raj Dattani, BMBCh